Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to External-Beam Radiation Therapy

This study is currently recruiting participants.
Verified March 2014 by Mayo Clinic
Sponsor:
Collaborator:
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00788307
First received: November 7, 2008
Last updated: March 10, 2014
Last verified: March 2014
  Purpose

RATIONALE: Radioactive drugs, such as radioactive iodine, may carry radiation directly to tumor cells and not harm normal cells. Placing a gene called Ad5CMV-NIS in prostate cancer cells may help the prostate cells take in more radioactive iodine and thus kill the cancer cells. Drugs, such as liothyronine sodium, may protect the thyroid from the side effects of radioactive iodine.

PURPOSE: This phase I trial is studying the side effects and best dose of gene therapy given together with radioactive iodine in treating patients with locally recurrent prostate cancer that did not respond to external-beam radiation therapy.


Condition Intervention Phase
Prostate Cancer
Biological: Ad5-CMV-NIS
Drug: liothyronine sodium
Genetic: reverse transcriptase-polymerase chain reaction
Other: laboratory biomarker analysis
Radiation: iodine I 131
Phase 1

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I Trial of In Situ Gene Therapy for Locally Recurrent Prostate Cancer Following Radiation Therapy Failure Using Sodium/Iodide Symporter and Radioiodine

Resource links provided by NLM:


Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Number of toxicity incidents by NCI CTCAE v3.0 criteria [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Time to PSA progression [ Designated as safety issue: No ]
  • Survival [ Designated as safety issue: No ]
  • Incidence and duration of PSA response [ Designated as safety issue: No ]
  • Duration of PSA control [ Designated as safety issue: No ]

Estimated Enrollment: 24
Study Start Date: July 2009
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • To determine the safety and tolerance of Ad5CMV-NIS administered intraprostatically followed by radioiodine treatment in patients with locally recurrent adenocarcinoma of the prostate following external beam radiotherapy.
  • To determine the maximum tolerated dose of Ad5CMV-NIS in these patients.

Secondary

  • To evaluate the PSA response rates, duration, and time to PSA progression in these patients.
  • To evaluate the immune response to Ad5CMV-NIS.

OUTLINE: This is a dose-escalation study of Ad5CMV-NIS.

Patients receive intraprostate Ad5CMV-NIS, via transperineal injection under anesthesia, on day 1. They receive dosimetry oral iodine I 123 on day 4 and undergo image studies periodically for the next 24 hours for measurement of radioiodine uptake. Patients receive therapeutic oral iodine I 131 on day 5.

All patients with intact thyroid glands (i.e., not previously surgically removed or ablated) receive TSH suppressive doses of oral liothyronine sodium 3 times daily for 10 days prior and for 15 days post administration of iodine I 123.

Blood samples are collected periodically for measurement of PSA, fT4, and TSH; and peripheral blood cells are monitored for evidence of virus DNA via quantitative reverse-transcriptase-PCR.

After completion of study therapy, patients are followed every 3 months for 1 year, every 4 months for 1 year, and then every 6 months for 8 years. A transrectal tumor biopsy is to be performed at 3 months and 1 year post-treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed recurrent adenocarcinoma of the prostate within the past year

    • No transitional cell, small cell, or squamous cell carcinoma of the prostate
    • Local recurrence
  • Disease recurred ≥ 18 months after completion of prior external beam radiotherapy (EBRT) for stage T1-T2b, N0/X, M0 disease

    • Biochemical failure as defined by the Phoenix definition (rise in PSA by 2 ng/mL or more above the nadir PSA)

      • PSA ≥ 0.3 ng/mL to < 20 ng/mL measured within the past 30 days
    • Pre-EBRT PSA < 50 ng/mL
    • Prior locally recurrent hormone-refractory disease allowed
  • American Urologic Association Obstructive Symptom Index Score ≤ 24
  • No known standard therapy that is potentially curative or definitely capable of extending life expectancy
  • No evidence of or history of metastatic adenocarcinoma of the prostate

    • Negative radiographic metastatic work-up including whole-body radionuclide bone scan, CT and/or MR scan of the pelvis and abdomen, and chest x-ray

      • Patients with suspicious areas on conventional imaging studies are eligible provided they are biopsy negative
    • No known CNS metastases
  • No prostate size > 140 cc

PATIENT CHARACTERISTICS:

  • ECOG performance status 0-2
  • Life expectancy ≥ 12 weeks
  • ANC ≥ 1,500/μL
  • Platelet count ≥ 100,000/μL
  • Hemoglobin ≥ 8.5 g/dL
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • INR ≤ 1.4 times ULN
  • Creatinine ≤ 1.5 times ULN
  • Thyroid-stimulating hormone 0.3-5.0 uIU/mL and free thyroxine 0.8-1.87 ng/dL
  • Willing to provide biologic specimens and participate in imaging studies as required
  • Willing to maintain a low-iodine diet for 12 days

    • Starting 7 days prior to study virus injection continuing until after the iodine I 131 radioiodine therapy on day 5
  • No more than 1 of the following renal/genitourinary toxicities:

    • Bladder spasms
    • Dysuria (painful urination)
    • Genitourinary fistula
    • Hemoglobinuria
    • Incontinence
    • Operative injury to bladder and/or ureter
    • Proteinuria
    • Renal failure
    • Uretal obstruction
    • Urinary frequency/urgency
    • Urinary retention
    • Urine color change (not related to other dietary or physiologic cause [e.g., bilirubin, concentrated urine, or hematuria])
    • Other renal/genitourinary toxicities
  • No urinary tract infection within 72 hours prior to registration
  • No pubic arch interference study demonstrating unacceptable prostate access by the transperineal approach
  • No absence of rectum or other anatomic features that would preclude transperineal needle insertion into the prostate
  • No coagulopathy that contraindicates transperineal and intraprostatic needle insertion
  • No other cancer within the past 2 years, except for squamous cell and basal cell skin cancers
  • No uncontrolled infection or fever > 100°F
  • No known cardiac disease
  • No seizure disorder
  • No documented history of HIV positivity or other acquired immunodeficiency disorder or congenital immunodeficiency disorder

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • Recovered from acute, reversible effects of prior chemotherapy
  • Androgen-deprivation therapy (if applicable) initiated more than 3 months prior to registration

    • Patients who have undergone bilateral orchiectomy are eligible if they meet all other criteria
  • At least 6 weeks since prior bicalutamide, nilutamide, or oral or intravenous iodinated contrast
  • At least 4 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas), immunotherapy, biologic therapy, or other experimental drugs
  • At least 4 weeks since prior and no concurrent anti-androgens (e.g., flutamide, estrogens, ketoconazole, PC-SPES, finasteride, or megestrol acetate)
  • At least 2 weeks since prior and no concurrent exogenous corticosteroids

    • Patients clinically proven to require maintenance steroids allowed provided there has been no change in their dose within the past 6 weeks
  • No antibiotic therapy within the past 72 hours
  • No prior organ transplantation
  • No prior salvage prostatectomy or brachytherapy
  • No other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational
  • No concurrent prophylactic use of colony-stimulating factors
  • No concurrent enrollment in any other study involving a pharmacologic agent (drugs, biologics, immunotherapy approaches, gene therapy) whether for symptom control or therapeutic intent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00788307

Locations
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Mayo Clinic Clinical Trials Office    507-538-7623      
Principal Investigator: Brian J. Davis, M.D.         
Sponsors and Collaborators
Mayo Clinic
Investigators
Study Chair: Brian J. Davis, M.D. Mayo Clinic
  More Information

Additional Information:
No publications provided

Responsible Party: Brian J. Davis, M.D., Mayo Clinic Cancer Center
ClinicalTrials.gov Identifier: NCT00788307     History of Changes
Other Study ID Numbers: MC0252, P30CA015083, MC0252, 06-009392, NCI-2009-01195
Study First Received: November 7, 2008
Last Updated: March 10, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Mayo Clinic:
adenocarcinoma of the prostate
recurrent prostate cancer
stage I prostate cancer
stage II prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Iodine
Anti-Infective Agents, Local
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Trace Elements
Micronutrients
Growth Substances
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 17, 2014